The acquisition of ProfoundBio by Genmab for $1.8 billion in cash is a significant strategic move, likely viewed positively by investors. This acquisition could potentially expand Genmab's portfolio and market presence, leading to an optimistic outlook on the company's future growth and profitability. Hence, the positive reaction in the stock price.